Article

Intracameral cefuroxime safe, effective for endophthalmitis

Intracameral administration of cefuroxime is a safe and effective alternative to subconjunctival delivery of the drug for the treatment of endophthalmitis after cataract surgery, according to research presented by Patrick Yu-Wai-Man, MRCOphth.

Intracameral administration of cefuroxime is a safe and effective alternative to subconjunctival delivery of the drug for the treatment of endophthalmitis after cataract surgery, according to research presented by Patrick Yu-Wai-Man, MRCOphth.

Dr. Yu-Wai-Man, of the Sunderland Eye Infirmary, Sunderland, United Kingdom, discussed results of a retrospective study of all presumed infectious endophthalmitis cases presenting at the institution from Jan. 1, 2000 to Dec. 31, 2006. He said it was the first study comparing the two delivery methods of cefuroxime.

In the United Kingdom, he said, 68% to 83% of ophthalmologists use subconjunctival delivery of cefuroxime and are reluctant to administer the drug intracamerally because the rate of endophthalmitis seen is deemed acceptable.

Before Nov. 16, 2003, all patients undergoing cataract surgery at his institution were treated with a uniform antibiotic protocol that included 5% povidone iodine solution and subconjunctival cefuroxime injection at the end of surgery, he said. After that date, all patients were given cefuroxime intracamerally.

At the institution, intracameral delivery of cefuroxime led to a three-fold reduction in the rate of endophthalmitis compared with subconjunctival administration, Dr. Yu-Wai-Man said.

Specifically, the rate per thousand of presumed infectious endophthalmitis was 1.39 in the group treated subconjunctivally (27 cases in 19,425 cataract procedures performed) and 0.46 in the group treated intracamerally (eight of 17,318). No cases of anterior segment toxicity were seen.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.